Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$127.81 USD

127.81
3,359,955

-12.71 (-9.04%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $127.83 +0.02 (0.02%) 7:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

Catalent Stock Flat Following the Sell Agreement With Ardena

by Zacks Equity Research

CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.

Zacks Equity Research

HealthEquity Gains 28.3% YTD: What's Driving the Stock?

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

Acadia Healthcare Ventures in South Carolina With Three Buyouts

by Zacks Equity Research

ACHC expands its CTC network by acquiring three opioid treatment program clinics in South Carolina.

Zacks Equity Research

Centene's Meridian Unit Wins Michigan Contract for HIDE SNP Plan

by Zacks Equity Research

CNC's Meridian subsidiary secures a contract to provide integrated Medicare and Medicaid services in Michigan through a new HIDE SNP program, which is expected to boost its member base and statewide presence.

Indrajit Bandyopadhyay headshot

Can DaVita Stock Continue Its Bull Run After Doubling in a Year?

by Indrajit Bandyopadhyay

DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.

Zacks Equity Research

DaVita Inc. (DVA) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Reasons to Retain PacBio Stock in Your Portfolio for Now

by Zacks Equity Research

PACB's strong product demand and continued focus on R&D raise optimism about the stock.

Zacks Equity Research

SNN Stock May Gain Following the Co-Marketing Deal With JointVue

by Zacks Equity Research

Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.

Zacks Equity Research

BDX Stock Up on Robotics Solution Launch to Boost Single-Cell Research

by Zacks Equity Research

BD aims to automate the complex library preparation process to aid researchers get consistent results and minimize the variability stemming from manual procedures.

Zacks Equity Research

SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device

by Zacks Equity Research

SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery.

Zacks Equity Research

Are Investors Undervaluing DaVita (DVA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

DaVita HealthCare (DVA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

The latest trading day saw DaVita HealthCare (DVA) settling at $159.43, representing a +0.08% change from its previous close.

Zacks Equity Research

Here's Why You Should Add Elevance Health Stock to Your Portfolio

by Zacks Equity Research

ELV benefits from an increase in employer group fee-based memberships, partially offsetting the impact of Medicaid memberships.

Zacks Equity Research

DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?

by Zacks Equity Research

DVA's strong performance and growth strategies, including patient-centric care and international expansion, position it well for continued success despite potential risks.

Zacks Equity Research

AMN Stock Down Despite WorkWise Launch to Enhance Healthcare Delivery

by Zacks Equity Research

AMN Healthcare aims to enhance staffing efficiency and improve operational efficiency in healthcare systems via the latest launch.

Zacks Equity Research

Here's Why You Should Add DaVita Stock to Your Portfolio Now

by Zacks Equity Research

DVA's strength in its kidney care business raises optimism about the stock.

Zacks Equity Research

Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Compelling Reasons to Hold on to Encompass Health Stock Right Now

by Zacks Equity Research

EHC remains well-poised for growth on the back of improved revenues, an extensive rehabilitation hospital network and sufficient cash-generating abilities.

Zacks Equity Research

DaVita HealthCare (DVA) Stock Moves -0.03%: What You Should Know

by Zacks Equity Research

In the latest trading session, DaVita HealthCare (DVA) closed at $159.07, marking a -0.03% move from the previous day.

Zacks Equity Research

Three Reasons Why You Should Hold BDX Stock in Your Portfolio Now

by Zacks Equity Research

BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.

Zacks Equity Research

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

by Zacks Equity Research

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Zacks Equity Research

SRDX Stock Down Despite FDA Clearance for Pounce XL System

by Zacks Equity Research

Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.

Vasundhara Sawalka headshot

5 Stocks Trading Near 52-Week High With Room to Rise Further

by Vasundhara Sawalka

Investors target stocks that have been on a bullish run lately. Stocks like THC, SLVM, DVA, NCLH and IAG are seeing price strength, and the momentum is likely to continue.

Zacks Equity Research

Reasons to Retain DexCom Stock in Your Portfolio for Now

by Zacks Equity Research

DXCM continues to raise optimism among investors, owing to its strong product portfolio.